Lymphoma Hub

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL)?This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What do the primary results from the EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 alone in patients with R/R FL?In this interview, Falchi highlights that epcoritamab and R2 do not have overlapping toxicities and that the combination may offer synergistic activity. He concludes that epcoritamab sets a new benchmark as a readily available treatment for patients with R/R FL.This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).In this interview, Abdulhaq discusses 3-year follow-up results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs rituximab (R)-GemOx in patients with R/R DLBCL who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT). They also discuss the efficacy and safety of Glofit-GemOx in clinically relevant patient subgroups.This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The discussion was preceded by a presentation by Gareth Gregory, chaired by Gilles Salles, and featured Ulrich Jäger, Francesc Bosch, Michael Dickinson, Astrid Pavlovsky, Marek Trněný, Alison Moskowitz, and Stefano Luminari. Gregory presented an overview of the STARGLO trial, efficacy and safety data, and key takeaways. This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence on the content of this resource.

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). The symposium concluded with a Q&A session, where the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the live audience. This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource